Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6871 AL 6885

The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases

Wright JW, Kawas LH, Harding JW.

Prog Neurobiol. 2015 Feb;125:26-46. doi: 10.1016/j.pneurobio.2014.11.004. Epub 2014 Nov 29.

Donepezil-induced myoclonus in a patient with Alzheimer disease

Bougea A, Gerakoulis S, Anagnostou E, Paraskevas G, Kapaki E, Kararizou E.

Ann Pharmacother. 2014 Dec;48(12):1659-61. doi: 10.1177/1060028014550334. Epub 2014 Sep 8.

Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors

Ikeda K, Yanagihashi M, Sawada M, Hanashiro S, Kawabe K, Iwasaki Y.

Intern Med. 2014;53(9):1007-10. doi: 10.2169/internalmedicine.53.1857. Epub 2014 May 1.

Tissue transglutaminase in Alzheimer's disease: involvement in pathogenesis and its potential as a therapeutic target

Wilhelmus MM, de Jager M, Bakker EN, Drukarch B.

J Alzheimers Dis. 2014;42 Suppl 3:S289-303. doi: 10.3233/JAD-132492.

Human-induced pluripotent stem cells: potential for neurodegenerative diseases

Ross CA, Akimov SS.

Hum Mol Genet. 2014 Sep 15;23(R1):R17-26. doi: 10.1093/hmg/ddu204. Epub 2014 May 13.

A network approach to clinical intervention in neurodegenerative diseases

Santiago JA, Potashkin JA.

Trends Mol Med. 2014 Dec;20(12):694-703. doi: 10.1016/j.molmed.2014.10.002. Epub 2014 Oct 30.

HtrA protease family as therapeutic targets

Skorko-Glonek J, Zurawa-Janicka D, Koper T, Jarzab M, Figaj D, Glaza P, Lipinska B.

Curr Pharm Des. 2013;19(6):977-1009. doi: 10.2174/1381612811319060003.

Mitochondria as a pharmacological target: magnum overview

Olszewska A, Szewczyk A.

IUBMB Life. 2013 Mar;65(3):273-81. doi: 10.1002/iub.1147.

Ghrelin as a neuroprotective and palliative agent in Alzheimer's and Parkinson's disease

Dos Santos VV, Rodrigues AL, De Lima TC, de Barioglio SR, Raisman-Vozari R, Prediger RD.

Curr Pharm Des. 2013;19(38):6773-90. doi: 10.2174/13816128113199990411.

Progress in stem cell therapy for major human neurological disorders

Martínez-Morales PL, Revilla A, Ocaña I, González C, Sainz P, McGuire D, Liste I.

Stem Cell Rev Rep. 2013 Oct;9(5):685-99. doi: 10.1007/s12015-013-9443-6.

Caring for parents with neurodegenerative disease: a qualitative description

Habermann B, Hines D, Davis L.

Clin Nurse Spec. 2013 Jul-Aug;27(4):182-7. doi: 10.1097/NUR.0b013e318295576b.

Can we teach old dogs new tricks? Neuroprotective cell therapy in Alzheimer's and Parkinson's disease

Kazmerova Z, Zilka N, Cente M, Neradil P, Zilkova M, Novak M.

J Alzheimers Dis. 2013;37(2):251-72. doi: 10.3233/JAD-130572.

Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration

Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, Plácido A, Santos MS, Oliveira CR, Moreira PI.

Biochim Biophys Acta. 2013 Apr;1832(4):527-41. doi: 10.1016/j.bbadis.2013.01.008. Epub 2013 Jan 11.

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases

Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G.

Transl Psychiatry. 2013 Dec 3;3(12):e332. doi: 10.1038/tp.2013.97.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias